Rocket Pharmaceuticals, Inc. (RCKT)Healthcare | Biotechnology | Cranbury, United States | NasdaqGM
2.18 USD
-0.18
(-7.627%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 2.23 +0.05 (2.339%) ⇧ (Oct. 16, 2026, 4:53 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 7:16 a.m. EDT
The fundamental reality here is stark: despite a recent FDA approval for a gene therapy, the stock has suffered a catastrophic 89.7% decline over the last nine years, with the most recent annual performance being a brutal 79% drop. The business is burning cash, showing negative returns on assets and equity, and trading at a negative forward P/E because it generates no earnings. While the balance sheet holds significant cash, the operational trajectory is clearly deteriorating, and the market has already priced in the failure of the pipeline to generate sustainable value. The recent price action confirms this pessimism, as the stock trades well below its 50-day and 200-day moving averages, indicating persistent selling pressure. With no dividend to provide income and a statistical forecast model admitting it cannot predict the next move due to extreme volatility, there is no clear edge for a short-term trader. The long-term outlook remains bleak given the multi-year structural decline and lack of profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.106593 |
| AutoETS | 0.117896 |
| MSTL | 0.120759 |
| AutoARIMA | 0.131215 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 2.64 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.723 |
| Market Cap | 239,308,640 |
| Forward P/E | -1.67 |
| Beta | 0.50 |
| Website | https://www.rocketpharma.com |
As of Oct. 10, 2026, 7:16 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts relative to calls. The put/call ratio is skewed significantly toward bearish bets, with traders buying deep strikes ($5.00, $7.50) to cap losses rather than speculate on a rally. This suggests a consensus view that the current price is vulnerable to further declines despite the recent FDA approval news.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3638814 |
| Address1 | 9 Cedarbrook Drive |
| All Time High | 77.8 |
| All Time Low | 2.17 |
| Ask | 4.02 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 2,498,090 |
| Average Daily Volume3 Month | 1,759,398 |
| Average Volume | 1,759,398 |
| Average Volume10Days | 2,498,090 |
| Beta | 0.497 |
| Bid | 2.95 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | 3.367 |
| City | Cranbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.18 |
| Current Ratio | 9.245 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.36 |
| Day Low | 2.17 |
| Debt To Equity | 6.723 |
| Display Name | Rocket Pharmaceuticals |
| Dividend Date | 1,515,110,400 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -182,176,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.108 |
| Enterprise Value | -19,640,378 |
| Eps Current Year | -0.1075 |
| Eps Forward | -1.302 |
| Eps Trailing Twelve Months | -0.17 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.2146 |
| Fifty Day Average Change | -1.0346 |
| Fifty Day Average Change Percent | -0.32184407 |
| Fifty Two Week Change Percent | -36.38814 |
| Fifty Two Week High | 5.45 |
| Fifty Two Week High Change | -3.2699997 |
| Fifty Two Week High Change Percent | -0.59999996 |
| Fifty Two Week Low | 2.17 |
| Fifty Two Week Low Change | 0.00999999 |
| Fifty Two Week Low Change Percent | 0.0046082903 |
| Fifty Two Week Range | 2.17 - 5.45 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,424,269,800,000 |
| Float Shares | 87,618,790 |
| Forward Eps | -1.302 |
| Forward P E | -1.6743472 |
| Free Cashflow | 86,136,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 202 |
| Fullday Change | -0.12899995 |
| Fullday Change Percent | -5.4660997 |
| Fullday Price | 2.18 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03181 |
| Held Percent Institutions | 0.91817003 |
| Implied Shares Outstanding | 109,774,597 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,515,110,400 |
| Last Split Factor | 1:4 |
| Long Business Summary | Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. |
| Long Name | Rocket Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 239,308,640 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_427906624 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -17,250,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 330,970,409 |
| Number Of Analyst Opinions | 12 |
| Open | 2.36 |
| Operating Cashflow | -170,267,008 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Phone | 609 659 8001 |
| Post Market Change | 0.05099988 |
| Post Market Change Percent | 2.339444 |
| Post Market Price | 2.231 |
| Post Market Time | 1,792,184,014 |
| Previous Close | 2.36 |
| Price Eps Current Year | -20.27907 |
| Price Hint | 4 |
| Price To Book | 0.64746064 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.06 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.14286 |
| Region | US |
| Regular Market Change | -0.18 |
| Regular Market Change Percent | -7.62711 |
| Regular Market Day High | 2.36 |
| Regular Market Day Low | 2.17 |
| Regular Market Day Range | 2.17 - 2.36 |
| Regular Market Open | 2.36 |
| Regular Market Previous Close | 2.36 |
| Regular Market Price | 2.18 |
| Regular Market Time | 1,792,180,800 |
| Regular Market Volume | 1,966,675 |
| Return On Assets | -0.28416002 |
| Return On Equity | -0.04772 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 109,774,597 |
| Shares Percent Shares Out | 0.1371 |
| Shares Short | 15,049,780 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 14,711,952 |
| Short Name | Rocket Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.168 |
| Short Ratio | 8.45 |
| Source Interval | 15 |
| State | NJ |
| Symbol | RCKT |
| Target High Price | 15.0 |
| Target Low Price | 2.95 |
| Target Mean Price | 8.57917 |
| Target Median Price | 9.5 |
| Total Cash | 283,747,008 |
| Total Cash Per Share | 2.585 |
| Total Debt | 24,798,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.523425 |
| Two Hundred Day Average Change | -1.343425 |
| Two Hundred Day Average Change Percent | -0.38128385 |
| Type Disp | Equity |
| Volume | 1,966,675 |
| Website | https://www.rocketpharma.com |
| Zip | 8,512 |